Moderna's new mRNA vaccine targets both flu and COVID-19, showing strong immune responses in trials, while non-celiac gluten ...
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Feb 18 (Reuters) - A two-in-one mRNA vaccine developed by Moderna that targets ...
Moderna’s efforts to advance its cancer pipeline “make sense” against the backdrop of a more skeptical U.S. government attitude toward infectious disease vaccines, the company’s oncology chief told ...
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results